govt.fyi
Back to SB 534
Arkansas General Assembly· SB 534Died in House at Sine Die adjournment.

An act TO ESTABLISH THE ARKANSAS KRATOM CONSUMER 10 PROTECTION ACT, the official text

Shown verbatim: the complete text as captured from the official PDF posted by the Arkansas General Assembly, fetched 2026-07-23. Page and line markers are part of the official record; nothing is edited or removed. The official bill page.
Stricken language would be deleted from and underlined language would be added to present law.

1 State of Arkansas           A Bill
2 95th General Assembly

3 Regular Session, 2025                                           SENATE BILL 534

4

5 By: Senator G. Leding

6 By: Representative Eubanks

7

8                             For An Act To Be Entitled

9   AN ACT TO ESTABLISH THE ARKANSAS KRATOM CONSUMER

10  PROTECTION ACT; TO REMOVE MITRAGYNINE AND 7-

11  HYDROXYMITRAGYNINE, ALSO KNOWN AS KRATOM, FROM THE

12  CONTROLLED SUBSTANCES LIST IN ARKANSAS; AND FOR OTHER

13  PURPOSES.

14

15

16                            Subtitle

17                       TO ESTABLISH THE ARKANSAS KRATOM

18                       CONSUMER PROTECTION ACT; AND TO REMOVE

19                       MITRAGYNINE AND 7-HYDROXYMITRAGYNINE,

20                       ALSO KNOWN AS KRATOM, FROM THE

21                       CONTROLLED SUBSTANCES LIST IN ARKANSAS.

22

23 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:

24

25  SECTION 1. Arkansas Code Title 20, Chapter 56, is amended to add an

26 additional subchapter to read as follows:

27  Subchapter 5 -- Arkansas Kratom Consumer Protection Act

28

29  20-56-501. Title.

30  This subchapter shall be known and may be cited as the "Arkansas Kratom

31 Consumer Protection Act".

32

33  20-56-502. Legislative findings.

34  The General Assembly finds that:

35  (1) On February 1, 2016, the Department of Health added

36 mitragynine and 7-hydroxymitragynine, which are two (2) constituent compounds

    *JMB567*                                               03/20/2025 12:06:46 PM JMB567
                                                                             SB534

1 of the kratom plant, as Schedule I substances;

2        (2) The Department of Health justified this action on the basis

3 that mitragynine and 7-hydroxymitragynine induce opioid-like effects when

4 consumed and included kratom as a Schedule I substance since it has no

5 approved medical use by the United States Food and Drug Administration;

6        (3)(A) The United States Food and Drug Administration had

7 encouraged every state to ban kratom on the premise that it would be

8 scheduled by the United States Drug Enforcement Administration as a

9 controlled substance in 2016 and that Alabama, Wisconsin, Indiana, and

10 Vermont had already classified kratom as a Schedule I substance.

11                  (B) Rhode Island also banned kratom in 2017 based on

12 information provided by the United State Food and Drug Administration;

13       (4) On October 13, 2016, the United States Drug Enforcement

14 Administration withdrew the United States Drug Enforcement Administration's

15 scheduling recommendation for kratom, citing insufficient evidence to meet

16 the requirements for classifying mitragynine and 7-hydroxymitragynine as

17 Schedule I substances;

18       (5) On August 16, 2018, the Assistant Secretary of Health of the

19 United States Department of Health and Human Services withdrew the United

20 States Food and Drug Administration's second scheduling recommendation for

21 mitragynine and 7-hydroxymitragynine as Schedule I substances citing

22 "disappointingly poor evidence and data and a failure to consider overall

23 public health";

24       (6) On December 1, 2021, the Expert Committee on Drug Dependence

25 at the United Nations Commission on Narcotic Drugs rejected the

26 recommendation for international scheduling of mitragynine and 7-

27 hydroxymitragynine citing insufficient evidence to support that action;

28       (7) On February 21, 2023, the Indiana House of Representatives,

29 on a vote of 53-40, passed a repeal of the kratom ban and replaced it with

30 the Kratom Consumer Protection Act;

31       (8)(A) On March 1, 2023, the Vermont Department of Health

32 accepted a petition by the American Kratom Association to remove the kratom

33 ban.

34                  (B) Upon completion of the planned rulemaking of the

35 Vermont Department of Health, the number of states with a kratom ban has been

36 reduced to five (5) states;

                                        2         03/20/2025 12:06:46 PM JMB567
                                                                            SB534

1              (9) On March 10, 2023, the Wisconsin Controlled Substances Board

2 passed a motion affirming to the Wisconsin State Legislature that kratom does

3 not meet the statutorily-mandated eight factors established by the Controlled

4 Substances Act for scheduling despite their view kratom should not be removed

5 from scheduling until more research is available;

6              (10) The Rhode Island Legislature is proceeding with the Kratom

7 Consumer Protection Act after the Interim Director of the Rhode Island

8 Department of Health acknowledged kratom does not meet the criteria for

9 scheduling;

10             (11) At this time, nine (9) states, including Utah, Georgia,

11 Arizona, Nevada, Oregon, Colorado, Oklahoma, West Virginia, and Virginia,

12 have passed versions of the Kratom Consumer Protection Act;

13             (12) On March 16, 2022, United States Department of Health and

14 Human Services Secretary Becerra, in a letter to Senator Mike Lee and

15 Representative Mark Pocan, acknowledged "knowledge gaps" on kratom and that

16 "kratom-involved overdose deaths have occurred after use of adulterated

17 kratom products or taking kratom with other substances";

18             (13) On December 29, 2022, President Joe Biden signed the FY23

19 Omnibus with kratom report language commending the National Institute on Drug

20 Abuse for funding studies on kratom that "may provide help for some Americans

21 struggling with addictions, given its analgesic and less addictive properties

22 as compared to opioids";

23             (14)(A) Data from the Department of Health shows that fatal

24 opioid overdoses have been on the rise in recent years.

25             (B) In 2021, the Department of Health reported there were

26 six hundred twenty-eight (628) drug overdose deaths in Arkansas; and

27             (15)(A) On May 17, 2022, the Director of the National Institute

28 on Drug Abuse, Dr. Nora Volkow, testified regarding the drug overdose crisis

29 at a hearing of the United States Senate Appropriations Subcommittee on

30 Labor, Health and Human Services, Education, and Related Agencies.

31             (B) When asked about overdose prevention strategies, Dr.

32 Volkow stated: "There's also interest in the community to test other products

33 that may serve as harm reduction. For example, the use of kratom, which is

34 sold as tea and that contains a drug molecule that has effects that are

35 similar to a dose of buprenorphine but could be utilized also for decreasing

36 withdrawal or depression."

                               3                     03/20/2025 12:06:46 PM JMB567
                                                                             SB534

1

2   20-56-503. Definitions.

3   As used in this subchapter:

4              (1) "Food" means a food, food product, food ingredient, dietary

5 ingredient, dietary supplement, or beverage for human consumption;

6              (2)(A) "Kratom product" means a food containing any part of the

7 leaf of the plant Mitragyna speciosa or an extract of the plant mitragyna

8 speciosa.

9                     (B) A "kratom product" may be manufactured as a powder,

10 capsule, pill, beverage, extract, or other edible form;

11             (3) "Kratom extract" means a food containing any part of the

12 leaf of the plant Mitragyna speciosa that has been extracted in order to

13 provide more standardized dosing;

14             (4) "Processor" means a person who sells, prepares,

15 manufactures, distributes, or maintains kratom products or advertises,

16 represents, or holds itself out as selling, preparing, or maintaining kratom

17 products; and

18             (5) "Retailer" means a person that sells, distributes,

19 advertises, represents, or holds itself out as selling or maintaining kratom

20 products.

21

22  20-56-504. Kratom product limitations.

23  A processor shall not prepare, distribute, sell, or expose for sale any

24 of the following:

25             (1) A kratom product that:

26                    (A)(i) Is adulterated with a dangerous non-kratom

27 substance.

28                    (ii) A kratom product is adulterated with a

29 dangerous non-kratom substance if the kratom product is mixed or packed with

30 a non-kratom substance and that substance affects the quality or strength of

31 the kratom product to such a degree as to render the kratom product injurious

32 to a consumer;

33                    (B)(i) Is contaminated with a dangerous non-kratom

34 substance.

35                    (ii) A kratom product is contaminated with a

36 dangerous non-kratom substance if the kratom product contains a poisonous or

                                      4     03/20/2025 12:06:46 PM JMB567
                                                                             SB534

1 otherwise deleterious non-kratom ingredient, including without limitation the

2 substances listed in the state's controlled substances list;

3   (C) Contains:

4   (i) A level of 7-hydroxymitragynine in the alkaloid

5 fraction that is greater than one percent (1%) of the overall alkaloid

6 composition of the product; or

7   (ii) Any synthetic alkaloids including synthetic

8 mitragynine, synthetic 7-hydroxymitragynine, or any other synthetically

9 derived compounds of the kratom plant;

10  (2) A kratom extract that contains levels of residual solvents

11 higher than is allowed in the U.S. Pharmacopeia Chapter 467; or

12  (3) A kratom product or kratom extract that does not provide

13 adequate labeling directions necessary for safe use by consumers, including a

14 recommended serving size, the recommended number of servings per day, and the

15 number of servings in the package that is sold.

16

17  20-56-505. Age limits.

18  A processor or retailer shall not distribute, sell, or expose for sale

19 a kratom product to an individual under eighteen (18) years of age.

20

21  20-56-506. Processor registration.

22  (a)(1) A processor shall register annually with the Department of

23 Agriculture any kratom product or kratom extract intended to be offered for

24 sale to an end consumer that is in an approved kratom delivery form and pay a

25 fee that is adjusted annually to cover all administrative costs for

26 processing and administering the registrations.

27  (2) The registration shall include a certificate of analysis

28 from a certified independent third-party laboratory showing compliance with

29 the requirements for kratom products or kratom extracts in this subchapter.

30  (b)(1) Upon receipt of a credible report of noncompliance with this

31 subchapter on a kratom product or kratom extract offered for sale, the

32 department shall require the processor to produce an updated and current

33 certificate of analysis in a reasonable time frame from a certified

34 independent third-party laboratory showing compliance with the requirements

35 of this subchapter for safe kratom products or kratom extracts.

36  (2) If the processor does not provide the certificate of

                                          5         03/20/2025 12:06:46 PM JMB567
                                                                             SB534

1 analysis in subdivision (b)(1) of this section in the specified time frame,

2 the registration for that kratom product or kratom extract shall be revoked.

3   (c)(1) Upon receipt of any adverse event related to a registered

4 kratom product or kratom extract, the processor shall submit a copy of the

5 adverse event report via certified mail to the department that is required to

6 be submitted to the United States Food and Drug Administration under Section

7 761 of the Federal Food, Drug, and Cosmetic Act.

8            (2) The department may revoke the kratom product's or kratom

9 extract's registration for any documented failure to report an adverse event

10 to the department.

11  (d)(1) If the department has a reasonable basis to require an

12 independent third-party test of a registered kratom product or kratom extract

13 by a laboratory of the department's choice, the processor shall be required

14 to submit payment for the test within a reasonable time frame.

15           (2) If the processor does not tender payment to the department

16 within a set time period upon receipt of the invoice for the testing, the

17 department shall revoke the registration for that kratom product or kratom

18 extract.

19

20  20-56-507. Violations.

21  (a)(1) A processor that violates this subchapter is subject to an

22 administrative fine of not more than five hundred dollars ($500) for the

23 first offense and not more than one thousand dollars ($1,000) for a second or

24 subsequent offense.

25           (2) Upon the request of a person to whom an administrative fine

26 is issued, the Secretary of the Department of Agriculture shall conduct a

27 hearing in accordance with the Arkansas Administrative Procedure Act, � 25-

28 15-201 et seq.

29  (b) A retailer does not violate this subchapter if it is shown by a

30 preponderance of the evidence that the retailer relied in good faith upon the

31 representations of a processor of food represented to be a kratom product or

32 kratom extract.

33

34

35

36

                            6                       03/20/2025 12:06:46 PM JMB567
Every fact on this page links to its source, starting with the official bill record.